There is the possibility that AML survival is independent of PARP1/2, whereas the other PARP family proteins are essential in AML cells; thus, targeting the other PARP family proteins may provide promising cytotoxic activities against leukemia in the clinic. This evidence concerns the gene PARP1 and acute myeloid leukemia.